Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XB 002 (Primary) ; Bevacizumab; Nivolumab
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Hypopharyngeal cancer; Laryngeal cancer; Male breast cancer; Non-small cell lung cancer; Oesophageal cancer; Oropharyngeal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms JEWEL-101
  • Sponsors Exelixis

Most Recent Events

  • 04 Apr 2025 Status changed from active, no longer recruiting to completed.
  • 15 Oct 2024 Planned End Date changed from 7 Feb 2025 to 31 Jul 2025.
  • 15 Oct 2024 Planned primary completion date changed from 7 Feb 2025 to 30 Apr 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top